Business
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup .com Ma...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect RealityIssued on behalf of Oncolytics Biotech Inc.\n\n\n\n VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) --\n \n\n USANewsGroup\n \n\n .com\n \n\n\n Market Intelligence Brief\n \n – Efficient Market Theory often fails in the small-cap sector. In this space, price discovery is slow. It lags behind the news. This creates a \"valuation disconnect\" where a company’s fundamental reality has shifted but the ticker remains anchored to an old story.\n \n\n For the disciplined investor, this lag is the signal.\n \n\n The following report analyzes five specific case studies of this phenomenon. We look at an immunotherapy priced as if its clinical wins never happened, an FDA-cleared AI platform valued as a hardware vendor, a permitted developer priced as an explorer, a US uranium validator priced as a grassroots hunter, and a strategic defense asset hidden inside a gold discovery. In each case, we believe the operational pivot has already occurred. The market, however, appears to lag behind the new information.\n \n\n\n 1. Oncolytics Biotech Inc.\n \n\n\n TICKER:\n \n (NASDAQ: ONCY)\n \n\n SECTOR:\n \n Immunotherapy / Oncology\n \n\n THE DISCONNECT:\n \n The market is pricing ONCY as another failed immunotherapy play. The reality: pelareorep is the activator designed to enable Big Pharma's patent-cliff checkpoint inhibitors to target cancers where they currently struggle.\n \n\n THE CATALYST:\n \n\n FDA-aligned Phase 3 trial initiation\n \n in first-line pancreatic cancer; the only immunotherapy registration study planned for this indication.\n \n\n MARKET CONTEXT:\n \n Pelareorep doesn't compete with Merck's Keytruda or Roche's Tecentriq. It primes tumors to unlock more potential efficacy from those drugs.\n \n\n THE INTELLIGENCE BRIEF:\n \n\n Oncolytics\n \n secured FDA alignment\n \n on a three-arm Phase 3 design testing pelareorep plus chemotherapy, with and without checkpoint inhibitors. The justification: a\n \n 62% objective response rate\n \n in pancreatic cancer when pelareorep was added to chemo and a checkpoint inhibitor, in a disease where immunotherapy has zero approved regimens.\n \n Two-year survival hit 21.9%\n \n versus the 9.2% historical standard.\n \n The mechanism is elegant. Pelareorep replicates inside cancer cells, ...